Typhoid Clinical Trial - Immune Non-inferiority & Safety of a Vi-DT

Status Active, not recruiting

Clinical Trial Summary

This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose.

The study objectives are:

I. Demonstrate non-inferiority of Vi-DT compared to Typbar TCV® as measured by seroconversion rates of anti-Vi IgG ELISA antibody titers, 4 weeks after single dose (pooled immunogenicity of three lots of Vi-DT)

II. Demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT of three lots of Vi-DT vaccine 4 weeks after single dose.

Clinical Trial Description

Subjects will be stratified according to age. The study procedure is as follows:

Visit 1 (day-1 to -7): Screen participants by medical/medications history, physical examination, Vital signs, Urine pregnancy test (UPT)

Visit 2 (day 0): Enroll, randomize and administer vaccine to eligible participants and assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments.

Visit 3 (day 7): Check solicited adverse reaction 7 days post vaccination and Assess participant safety by physical examination and Vital signs

Visit 4 (day 28): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments

Visit 5 (day 84): Assess participant safety by physical examination and Vital signs

Visit 6 (day 168): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments, and fill in study completion form in the absence of any safety concern.

This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine administrator.

For retention: After vaccination, field health worker/designee will contact participant every day till Day 7 by physical visit or by phone call. Follow-up reminder calls will be done very frequently as per discretion of study staff until 24 weeks for all participant to assess participant safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03933098
Study type	Interventional
Source	International Vaccine Institute
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	November 15, 2019
Completion date	January 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03312699` - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort	Phase 1
Completed	`NCT01405521` - Understanding Typhoid Disease After Vaccination	Phase 2
Completed	`NCT00131833` - Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China	Phase 4
Completed	`NCT00125047` - Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood	Phase 4
Not yet recruiting	`NCT05771779` - Co-administration Study of OCV, TCV and MR	Phase 3
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT00679172` - Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults	Phase 2
Completed	`NCT00125008` - Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever	Phase 4
Recruiting	`NCT04878549` - Transcriptomic Responses for the Identification of Pathogens
Completed	`NCT02645032` - Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine	Phase 1
Recruiting	`NCT05475379` - Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh	Phase 1/Phase 2
Completed	`NCT04204096` - Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)	Phase 3
Active, not recruiting	`NCT03299426` - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi	Phase 3
Completed	`NCT01019083` - Studies of Immune Responses to Orally Administered Vaccines in Developing Country	Phase 1/Phase 2
Completed	`NCT03614533` - Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso	Phase 2
Completed	`NCT00131820` - Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam	Phase 4
Completed	`NCT03527355` - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms